Champions Oncology IncNASDAQ:CSBR
- LAST PRICE5.0600
- TODAY'S CHANGE (%)0.0300 (0.5964%)
- Bid / Lots5.0300/ 5
- Ask / Lots5.3100/ 1
- Open / Previous Close5.1385 / 5.0300
- Day Range
- 52 Week Range
- Volume1,477
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CSBR |
|---|---|---|
| 10:32 ET | 100 | 5.1385 |
| 03:59 ET | 700 | 5.06 |
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Champions Oncology Inc | 68.4M | -7.0x | --- |
Precision BioSciences Inc | 67.9M | -0.9x | --- |
Bioqual Inc | 67.1M | -146.6x | -25.28% |
Centogene NV | 12.8M | -0.3x | --- |
Cidara Therapeutics Inc | 56.1M | -51.4x | --- |
Neptune Wellness Solutions Inc | 226.6K | 0.0x | --- |
Company Information
Champions Oncology, Inc. is a technology-enabled research organization engaged in creating transformative technology solutions to be utilized in drug discovery and development. The Company's research center operates in both regulatory and non-regulatory environments and consists of a comprehensive set of computational and experimental research platforms. The Company’s TumorGraft Technology Platform (The Platform) provides select services to pharmaceutical and biotechnology companies. Its software as-a-service business is centered around its software platform and data tool, Lumin Bioinformatics (Lumin), which contains comprehensive information derived from its research services and clinical studies. Its drug discovery and development business leverage the computational and experimental capabilities within its platforms. Its discovery strategy utilizes its datacenter, coupled with artificial intelligence and other advanced computational analytics, to identify therapeutic targets.
Contact Information
- Headquarters
- SUITE 619, 855 N. WOLFE STREETBALTIMORE, MD, United States 21205
- Phone
- 410-369-0365
- Fax
- 302-636-5454
Executives
- Independent Chairman of the Board
- Joel Ackerman
- President
- Brady Davis
- Chief Executive Officer, Director
- Ronnie Morris
- Chief Financial Officer
- David Miller
- Lead Independent Director
- David Sidransky
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $68.4M |
|---|---|
Revenue (TTM) | $49.2M |
Shares Outstanding | 13.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.39 |
EPS | $-0.72 |
Book Value | $0.34 |
P/E Ratio | -7.0x |
Price/Sales (TTM) | 1.4 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -19.51% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
